Aclarion Q1 EPS Boosted by Ascendiant Capital Markets

Aclarion, Inc. (NASDAQ:ACON) – Investment analysts at Ascendiant Capital Markets upped their Q1 2026 EPS estimates for Aclarion in a note issued to investors on Wednesday, March 25th. Ascendiant Capital Markets analyst L. Ward now expects that the company will earn ($1.55) per share for the quarter, up from their prior forecast of ($2.79). The consensus estimate for Aclarion’s current full-year earnings is ($263.33) per share. Ascendiant Capital Markets also issued estimates for Aclarion’s Q2 2026 earnings at ($0.95) EPS, Q3 2026 earnings at ($1.00) EPS, Q4 2026 earnings at ($1.09) EPS and FY2026 earnings at ($4.37) EPS.

Other research analysts have also recently issued reports about the company. Wall Street Zen upgraded Aclarion from a “sell” rating to a “hold” rating in a report on Saturday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aclarion in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

Aclarion Trading Up 0.7%

ACON stock opened at $3.08 on Monday. The firm has a 50-day moving average of $3.06 and a two-hundred day moving average of $5.47. Aclarion has a 12 month low of $2.34 and a 12 month high of $13.69. The company has a market cap of $7.02 million, a price-to-earnings ratio of -0.18 and a beta of 1.44.

Aclarion (NASDAQ:ACON) last posted its quarterly earnings results on Wednesday, March 18th. The company reported ($2.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.60) by $1.59. Aclarion had a negative net margin of 9,517.11% and a negative return on equity of 52.31%. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.02 million.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.